Patients with KRAS-mutant PDAC, NSCLC, and CRC are presently being treated by mRNA-5671/V941, a vaccination targeted to the KRAS-mutant peptides (G12D, G12C, G13D, and G12V) (ClinicalTrials.gov identifier: NCT03948763). This evidence concerns the gene KRAS and colorectal carcinoma.